

# **Colorado COVID-19 Response**

**distribution model for the allocation of  
limited availability therapeutics**

**Eric France MD MSPH**

**Chief Medical Officer, CDPHE**

**December 16, 2020**

# Principles for Allocation: Colorado Model

COVID-19 therapeutic distribution model

1. **Geographic Distribution:** to assure access for all Coloradans.
2. **Balance by need:** regions with higher risk or higher cases should receive more doses.
3. **Equitable access:** random allocator tool if more cases than doses.



# Catchment Area Model


COVID-19 therapeutic distribution model

 catchment area boundary

 90 minute one-way road travel time polygon from selected site

 current or proposed optimal infusion site

 population weighted road travel centroid






# Catchment Area Model

## COVID-19 therapeutic distribution model

These proposed catchment areas with the established or candidate infusion center sites result in **>98% being able to access one or more sites within 90 minutes** travel time from home.

- 5,423,662 cumulative population inside a 90 minute travel polygon
- 107,479 cumulative population outside a 90 minute travel polygon

2014-2018 pop estimates





# Design Steps

COVID-19 therapeutic distribution model

- 3. Tranche** each therapeutic allocation to each catchment area according to 1) risk index and 2) new infections.
- Measure the **proportion of COVID-19 risk** in each catchment area relative to proportion of COVID-19 risk statewide using a multivariant analysis of putative risk factors for COVID-19 complications.
  - Measure the **proportion of new COVID-19 infections** over the previous 14 day period in each catchment area relative to the total new infections in the state.

# Tranche Method

COVID-19 therapeutic distribution model

$$\text{Catchment area percent of therapeutic allocation} = \frac{(\text{proportional risk index burden} \times \text{proportion of new infections over previous 14 day period})}{2}$$

# Proportion of COVID-19 Risk Model

COVID-19 therapeutic distribution model

## Demographic Indicators

- Age: 50+, 65+, 50-64 and 65+
- Crowding
- Income: 125%, 200% and 300% of Federal Poverty Level
- Race and Ethnicity
- Sex

## Health Status Indicators

- Asthma
- Cancer
- Chronic kidney disease
- Chronic Obstructive Pulmonary Disease
- Heart disease
- Hypertension
- Immunocompromised state from solid organ transplant
- Obesity (BMI of 30 or higher)
- Sickle cell disease
- Smoking
- Type 2 diabetes

# Proportion of COVID-19 Risk Model

COVID-19 therapeutic distribution model

## Demographic Indicators

- Age: ~~50+~~, ~~65+~~, ~~50-64~~ and **65+**
- ~~Crowding~~
- Income: ~~125%~~, **200%** and ~~300%~~ of Federal Poverty Level
- ~~Race and Ethnicity~~ -> **Hispanic**
- ~~Sex~~ -> **Male**

## Health Status Indicators

- ~~Asthma~~
- ~~Cancer~~
- ~~Chronic kidney disease~~
- **Chronic Obstructive Pulmonary Disease**
- **Heart disease**
- ~~Hypertension~~
- ~~Immunocompromised state from solid organ transplant~~
- **Obesity** (BMI of 30 or higher)
- ~~Sickle cell disease~~
- ~~Smoking~~
- **Type 2 diabetes**



# Tranche Results

COVID-19 therapeutic distribution model

Distribution Center	Catchment Area Population	Proportion of 14-Day Infections	Proportion of Risk Burden	Allocation
Craig/Steamboat Springs	56,005	0.82%	1.01%	0.91%
Fort Collins	356,938	4.95%	6.25%	5.60%
Greeley	323,763	5.76%	5.18%	5.47%
Sterling	62,147	1.51%	1.18%	1.34%
Boulder	404,141	4.13%	6.98%	5.55%
Glenwood Springs	139,301	2.49%	2.40%	2.44%
Wheatridge	488,047	7.41%	8.55%	7.98%
Denver West	405,762	5.88%	7.16%	6.52%
Denver East	389,918	5.99%	6.78%	6.39%
Denver Central	389,918	5.99%	6.78%	6.39%
Aurora North	440,515	7.75%	7.43%	7.59%
Aurora South	440,515	7.75%	7.43%	7.59%
Grand Junction	233,805	4.59%	4.41%	4.50%
Highlands Ranch	378,214	5.29%	5.56%	5.42%
Burlington	24,708	1.24%	0.48%	0.86%
Gunnison	38,675	0.44%	0.73%	0.59%
Colorado Springs	747,848	14.95%	12.88%	13.92%
Pueblo	266,474	9.19%	5.41%	7.30%
Lamar	22,871	1.32%	0.47%	0.90%
Durango	107,371	1.93%	1.99%	1.96%
Alamosa	47,040	0.62%	0.94%	0.78%

# Random Allocator

CDPHE



**COLORADO**  
Department of Public  
Health & Environment

Resize font:  


COVID-19 Medication Random Allocation Process

Page 6 of 7

Random Allocation Process

This patient qualifies, please select "Next Page" to see whether or not this patient has been allotted Bamlanivimab or Casirivimab/Imdevimab (Regeneron)

<< Previous Page

Next Page >>



# Random Allocator

CDPHE



**COLORADO**  
Department of Public  
Health & Environment

Resize font:  
+ | -

COVID-19 Medication Random Allocation Process

Page 7 of 7

Random Allocation Process Outcome

This patient has been selected and can be scheduled to receive either Bamlanivimab or Casirivimab/Imdevimab (Regeneron).

This is the result of the real-time random allocation process.

Please select the Infusion Center for this patient below. After you do so and click "Submit" please download the PDF of the information you have entered. The PDF also includes this random allocation process outcome. This PDF will not be sent via email for confidentiality reasons.

Please select the Infusion Center that should receive these random allocation process results

▼

\* must provide value

# Challenges

CDPHE

- We need more infusion sites. Standing up a site takes time.
  - Random allocation based on infusion seats vs. therapeutic doses?
- Care delivery systems are saying “no thank you”:
  - Hospital and staff are busy with COVID-19 patients
  - Pediatrics: none in the state. Children’s hospital not interested: no data
- State resources: Project manager, data person, communications plan, CMO oversight, GIS & RedCAP programming.



# **distribution model for the allocation of limited availability therapeutics**

**Tamara Davis, MS, Devon Williford, MPH, and Steve Holloway, MPH**  
**December 16, 2020**